NASDAQ: ALPN

In a multibillion-dollar deal within the biotechnology sector, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leader in genetic disease treatment, has entered into an agreement to acquire Alpine Immune Sciences (NASDAQ: ALPN), a U.S.-based company specializing in protein engineering for immunotherapies. The transaction, valued at approximately USD 4.9 billion, is anticipated…